Experimental COVID-19 vaccine offers long-term protection against severe disease — ScienceDaily

by admin
0 comment

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine, and the New York Presbyterian will report a Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances the immune response. Did. , elicited a durable neutralizing antibody response to SARS-CoV-2 during early childhood in a preclinical study.

Currently, a follow-up study by the same group Science Translational Medicinefound that a two-dose vaccine still provided protection against lung disease in rhesus monkeys one year after vaccination in childhood.

The co-lead authors of this paper are Kristina De Paris, Ph.D., Professor of Microbiology and Immunology, UNC School of Medicine, Sallie Permar, M.D., Ph.D., Chair of Pediatrics, Weill Cornell Medicine, and Koen KA Van Rompay. , DVM, PhD, Leader of the Infectious Diseases Unit of the California National Primate Research, University of California, Davis. Co-lead authors are her Emma C. Milligan, Pediatric Research Institute, UNC School of Medicine, and her Katherine Olstad, California National Primate Research Center.

To evaluate vaccination of SARS-CoV-2 infants, researchers immunized two groups of eight rhesus monkeys at the California National Primate Research Center at 2 months and 4 weeks of age. Each animal received two vaccines: a preclinical version of the Moderna mRNA vaccine, or a protein combination vaccine developed by the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. received one of the Potent adjuvant formulation. This adjuvant formulation, which consists of 3M’s molecular adjuvant 3M-052 formulated into a squalene emulsion by the Access to Advanced Health Institute (AAHI), stimulates the immune response by engaging immune cell receptors.

“We followed up our SARS-CoV-2 infant rhesus monkey study, giving the animals a high-dose challenge with a SARS-CoV-2 variant one year later, and assessed the persistence of the vaccine-induced immune response and its efficacy. “Both vaccines are effective against lung disease,” said Dr. It has been found to protect against

Overall, the adjuvanted protein vaccine candidates maintained higher levels of neutralizing antibodies and provided superior protection compared to mRNA vaccines, Dr. De Paris said. These data demonstrate that these vaccines are safe and highly effective when administered to young macaque monkeys. Furthermore, the results will aid in the optimization and development of SARS-CoV-2 vaccines, reducing the need for frequent boosters and targeting special populations with underdeveloped immune systems, such as young children. may protect.

“Young infants are one of the most vulnerable pediatric populations due to COVID-19. SARS-CoV-2, influenza, and RSV circulation this fall,” said Nancy C. Paduano, professor of pediatrics at Weill Cornell Medicine. said Dr. Permar, who is also chief pediatrician at NewYork-Presbyterian Komansky Children’s Hospital. “We will take every opportunity to provide our youngest patient with safe and effective vaccine immunity, including considering vaccinating her against COVID-19 earlier than the currently recommended 6 months of age. need to do it.”

“This study highlights the need to vaccinate human infants against SARS-CoV-2 as much as possible, as the benefits are clear and long-lasting. It also emphasizes the value of the model,” said Dr. Van Rompay. He said. “The lessons we have learned and the resources and tools developed in our current research will help us prepare for future pandemics to more effectively combat outbreaks of novel coronaviruses or other respiratory viruses in the pediatric population. very valuable to the

This study was supported by the National Institutes of Health (P01AI117915-06S1), (U54 CA260543), (P510D11107), (UM1 AI068618-15: HVTN/HPTN, CoVPN), (P30AI050410: UNC Center for AIDS Research), and (P30 CA016086 : UNC-LCCC Flow Cytometry Core Facility).

Other authors include Caitlin A. Williams, Michael Mallory, Patricia Cano, Kaitlyn A. Cross, Jennifer E. Munt, Carolina Garrido, Lisa Lindesmith, Jennifer Watanabe, Jodie L. Usachenko, Lincoln Hopkins, Ramya Immareddy, Yashavanth Shaan Lakshmanappa, I’m Sonny R. Elizaldi, Jamin W. Law, Rebecca L. Samak, Joan L. Yi, Savannah Harbeck, Trover Scoby, Dieter Mielke, Genevieve Huda, Guido Ferrari, Hongmei Gao, Xiaoying Shen, Pamela A. Kozlowski, David Montefiore, Michael Hudgens, Darin K. Edwards, Andrea Carfi, Kizzmekia S. Corbett, Barney S. Graham, Christopher B. Fox, Mark Tomai, Smita S. Iyer, Ralph Baric, Rachel Reader, and Dirk P. Dittmer.

You may also like

Leave a Comment